BR112021021860A2 - Composição farmacêutica e composição cosmética para prevenir ou tratar a perda de cabelo - Google Patents
Composição farmacêutica e composição cosmética para prevenir ou tratar a perda de cabeloInfo
- Publication number
- BR112021021860A2 BR112021021860A2 BR112021021860A BR112021021860A BR112021021860A2 BR 112021021860 A2 BR112021021860 A2 BR 112021021860A2 BR 112021021860 A BR112021021860 A BR 112021021860A BR 112021021860 A BR112021021860 A BR 112021021860A BR 112021021860 A2 BR112021021860 A2 BR 112021021860A2
- Authority
- BR
- Brazil
- Prior art keywords
- preventing
- composition
- hair loss
- treating hair
- pharmaceutical composition
- Prior art date
Links
- 201000004384 Alopecia Diseases 0.000 title abstract 4
- 208000024963 hair loss Diseases 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 230000003676 hair loss Effects 0.000 title abstract 3
- 239000002537 cosmetic Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000018866 Hyaluronan Receptors Human genes 0.000 abstract 1
- 108010013214 Hyaluronan Receptors Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 abstract 1
- 229940099552 hyaluronan Drugs 0.000 abstract 1
- 229920002674 hyaluronan Polymers 0.000 abstract 1
- 230000003752 improving hair Effects 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 102000028619 proteoglycan binding proteins Human genes 0.000 abstract 1
- 108091009335 proteoglycan binding proteins Proteins 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1741—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals alpha-Glycoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Birds (AREA)
- Marine Sciences & Fisheries (AREA)
- Molecular Biology (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
uso da composição para preparar medicamento para prevenir ou tratar a perda de cabelo e composição cosmética para prevenir ou melhorar a perda de cabelo. a presente invenção refere-se a uma composição farmacêutica para prevenção ou tratamento da perda de cabelo, sendo que a composição compreende a proteína de ligação de hialuronano e proteoglicano 1 (hapln1) como um ingrediente ativo. quando administrada, a proteína hapln1 da presente invenção promove a proliferação de células matrizes germinais capilares através da trajetória de sinalização ras-erk1/2 ativada por uma proteína de tgf-ß, fazendo, assim o cabelo crescer.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20190050698 | 2019-04-30 | ||
| KR1020200051429A KR102390418B1 (ko) | 2019-04-30 | 2020-04-28 | Hapln1을 포함하는 탈모 예방 또는 치료용 조성물 |
| PCT/KR2020/005703 WO2020222538A2 (ko) | 2019-04-30 | 2020-04-29 | Hapln1을 포함하는 탈모 예방 또는 치료용 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021021860A2 true BR112021021860A2 (pt) | 2021-12-21 |
Family
ID=73028862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021021860A BR112021021860A2 (pt) | 2019-04-30 | 2020-04-29 | Composição farmacêutica e composição cosmética para prevenir ou tratar a perda de cabelo |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220202899A1 (pt) |
| EP (1) | EP3964223A4 (pt) |
| JP (1) | JP7182816B2 (pt) |
| CN (1) | CN113784723A (pt) |
| AU (1) | AU2020265476A1 (pt) |
| BR (1) | BR112021021860A2 (pt) |
| CL (1) | CL2021002853A1 (pt) |
| IL (1) | IL287659A (pt) |
| MX (1) | MX2021013349A (pt) |
| PE (1) | PE20220335A1 (pt) |
| SG (1) | SG11202112030SA (pt) |
| WO (1) | WO2020222538A2 (pt) |
| ZA (1) | ZA202109732B (pt) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011011593A1 (en) * | 2009-07-23 | 2011-01-27 | Aderans Research Institute, Inc. | Identity markers |
| US8334136B2 (en) * | 2009-07-24 | 2012-12-18 | Shiseido Company, Ltd. | Method for promoting hair growth or hair regeneration by maintaining or increasing expression of cell-adhesion factor |
| WO2013063155A2 (en) * | 2011-10-24 | 2013-05-02 | Halozyme, Inc. | Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof |
| MX2014014898A (es) * | 2012-06-06 | 2015-03-04 | Procter & Gamble | Sistemas y metodos de identificacion de agentes cosmeticos para composiciones para el cuidado del cabello/cuero cabelludo. |
| WO2016006885A1 (ko) * | 2014-07-07 | 2016-01-14 | 메디포스트(주) | 자극된 줄기세포 배양액의 발모 촉진능 및 이의 용도 |
| KR101897340B1 (ko) * | 2015-09-09 | 2018-09-13 | 중앙대학교 산학협력단 | Hapln1을 이용한 피부 노화 측정 또는 예방 또는 개선용 조성물 |
| KR101900748B1 (ko) * | 2016-08-17 | 2018-09-20 | (주)진셀팜 | 모발 성장 촉진 효과를 가지는 펩타이드, 및 이의 용도 |
| WO2019045451A1 (ko) * | 2017-08-29 | 2019-03-07 | 중앙대학교 산학협력단 | Hapln1을 유효성분으로 함유하는 연골 재생용 조성물 |
| KR20190024727A (ko) * | 2017-08-29 | 2019-03-08 | 중앙대학교 산학협력단 | Hapln1을 유효성분으로 함유하는 연골 재생용 조성물 |
-
2020
- 2020-04-29 EP EP20799504.4A patent/EP3964223A4/en not_active Withdrawn
- 2020-04-29 PE PE2021001803A patent/PE20220335A1/es unknown
- 2020-04-29 WO PCT/KR2020/005703 patent/WO2020222538A2/ko unknown
- 2020-04-29 CN CN202080032625.XA patent/CN113784723A/zh active Pending
- 2020-04-29 MX MX2021013349A patent/MX2021013349A/es unknown
- 2020-04-29 JP JP2021563100A patent/JP7182816B2/ja active Active
- 2020-04-29 US US17/607,765 patent/US20220202899A1/en active Pending
- 2020-04-29 AU AU2020265476A patent/AU2020265476A1/en active Pending
- 2020-04-29 SG SG11202112030SA patent/SG11202112030SA/en unknown
- 2020-04-29 BR BR112021021860A patent/BR112021021860A2/pt unknown
-
2021
- 2021-10-28 IL IL287659A patent/IL287659A/en unknown
- 2021-10-29 CL CL2021002853A patent/CL2021002853A1/es unknown
- 2021-11-29 ZA ZA2021/09732A patent/ZA202109732B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202112030SA (en) | 2021-12-30 |
| CN113784723A (zh) | 2021-12-10 |
| US20220202899A1 (en) | 2022-06-30 |
| IL287659A (en) | 2021-12-01 |
| JP7182816B2 (ja) | 2022-12-05 |
| WO2020222538A9 (ko) | 2021-02-25 |
| ZA202109732B (en) | 2022-09-28 |
| AU2020265476A1 (en) | 2022-01-06 |
| EP3964223A4 (en) | 2023-01-18 |
| MX2021013349A (es) | 2022-02-03 |
| PE20220335A1 (es) | 2022-03-14 |
| WO2020222538A3 (ko) | 2021-01-14 |
| WO2020222538A2 (ko) | 2020-11-05 |
| CL2021002853A1 (es) | 2022-06-17 |
| EP3964223A2 (en) | 2022-03-09 |
| JP2022530077A (ja) | 2022-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018004536A2 (pt) | peptídeos de endereçamento à cartilagem | |
| BRPI0510428A (pt) | composições tópicas de metadona e processos para utilização das mesmas | |
| BR112019024264A2 (pt) | Antimitoscinas: inibidores direcionados da biogênese mitoconcrial para erradicação de células-tronco de câncer | |
| BR112019008431A2 (pt) | aplicação de (s)-norcetamina e sal da mesma como fármaco | |
| CO5640037A2 (es) | Derivados de la quinazolina para el tratamiento del cancer | |
| BR112022001324A2 (pt) | Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo | |
| BR112014018421A8 (pt) | Composições antimicrobianas compreendendo dgla, 15-ohepa e/ou 15-hetre e métodos de uso das mesmas | |
| CL2021000207A1 (es) | Nuevas proteínas de fusión específicas para cd137 y pd-l1 | |
| BR112021015751A2 (pt) | Vetores de terapia genética para tratamento da doença de danon | |
| BR112023006024A2 (pt) | Terapias de imuno-oncologia com conjugados de il-2 | |
| BRPI0416275A (pt) | métodos de tratar, controlar ou prevenir um cáncer especìfico e uma doença associada com angiogênese indesejada | |
| BR112019017393A8 (pt) | Composição farmacêutica de evolocumab e seu uso, kit, método para preparar polipeptídeo de ligação a pcsk9 e método para formular polipeptídeo terapêutico | |
| BR112021018506A2 (pt) | Terapia de combinação para tratamento do câncer | |
| BR112013010829B8 (pt) | Composição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação | |
| BR112019023260A2 (pt) | Fatores de crescimento de fibroblastos recombinantes modificados e seus usos terapêuticos | |
| CO2023005057A2 (es) | Compuestos y composiciones como moduladores de señalización tlr | |
| CO2022018636A2 (es) | Moduladores de il-17a | |
| CO2022016899A2 (es) | Moduladores de il-17a | |
| CO2021013171A2 (es) | Compuestos y composiciones como moduladores de la señalización de tlr | |
| BR112022019518A2 (pt) | Composição farmacêutica para prevenir ou tratar mucosite induzida por radioterapia, quimioterapia, ou uma combinação das mesmas, que compreende derivados de glp-2 ou um conjugado de atuação duradoura do mesmo | |
| BR112021021860A2 (pt) | Composição farmacêutica e composição cosmética para prevenir ou tratar a perda de cabelo | |
| CO2021014968A2 (es) | Composición para la prevención o el tratamiento de la caída del cabello que incluye hapln1 | |
| AU2013378873B2 (en) | Histo-equivalent bioplastic material | |
| BR112019001082A2 (pt) | gel intestinal de levodopa e carbidopa e métodos de uso | |
| BR112022008357A2 (pt) | Composições e métodos para a distribuição de canabinoides à pele |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 4A ANUIDADE. |